Condition

Nervous System Diseases

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 54 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials54

Recruiting10

Common interventions25

Lead sponsors shown15

Clinical trials

54 shown

Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility StudyNCT07759115 · 2026-08-10

Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical ActivityNCT07324330 · 2025-12-04

Slow-SPEED: Slowing Parkinson's Early Through Exercise DosageNCT06993142 · 2025-09-01

Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-NetherlandsNCT06193252 · 2024-01-15

A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, ChinaNCT05886114 · 2023-05-28

Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's DementiaNCT06088121 · 2023-05-15

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MSNCT05834855 · 2023-04-01

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)NCT05565833 · 2023-02-27

Application of AI Technology for the Diagnosis and Treatment of Geriatric DiseasesNCT06295263 · 2022-03-01

Neurologic Stem Cell Treatment StudyNCT02795052 · 2016-06-01

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisNCT06677710 · 2026-06-30

Digital Diagnostics and Intervention Services for Parkinson's DiseaseNCT06534177 · 2024-10-15

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationNCT05321498 · 2023-06-01

Ukulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility StudyNCT05792176 · 2023-03-27

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)NCT05738486 · 2023-02-28

ACTIVE_NOT_RECRUITING

An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseNCT05522387 · 2023-02-21

Home-based Neuromodulation to Target Depression And Memory Symptoms in Older AdultsNCT05976659 · 2023-01-24

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)NCT05508789 · 2022-10-10

ACTIVE_NOT_RECRUITING

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationNCT05318976 · 2022-02-28

Harmony at Home: A Pilot Telehealth Program for Rural ADRD CaregiversNCT05202223 · 2022-01-15

Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's DiseaseNCT04871464 · 2021-11-11

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced DyskinesiaNCT04912115 · 2021-10-05

Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care SystemsNCT05080777 · 2021-09-28

The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) StudyNCT05007353 · 2021-08-23

Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years OldNCT04897113 · 2021-05-12

Aerobic Exercise for Remyelination in Multiple SclerosisNCT04539002 · 2021-04-29

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or NatalizumabNCT04837651 · 2021-03-02

A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese PopulationNCT05527288 · 2021-01-28

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi SyndromeNCT05657860 · 2020-12-17

Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)NCT04289909 · 2020-12-01

The Personalized Parkinson Project De Novo CohortNCT04985539 · 2020-08-29

ACTIVE_NOT_RECRUITING

Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary SclerosisNCT03540485 · 2019-11-29

Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the SmartphoneNCT03762902 · 2019-04-30

Long-Term Follow-up Safety After DDS Implantation With/Without CDNF InfusionsNCT04228653 · 2019-03-20

Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With OcrevusNCT03562975 · 2018-07-23

Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical StudyNCT03775538 · 2018-07-05

Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's DiseaseNCT03295786 · 2017-09-26

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's DiseaseNCT03065192 · 2017-05-11

Individualized Prediction of Migraine Attacks Using a Mobile Phone App and FitbitNCT02910921 · 2016-11-01

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple SclerosisNCT01453764 · 2016-04-01

Intrathecal Rituximab in Progressive Multiple SclerosisNCT02545959 · 2015-11-30

CNS Tau Kinetics in Healthy Aging and Alzheimer's DiseaseNCT03938870 · 2015-08-18

Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral AripiprazoleNCT02219009 · 2014-08-01

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or PlaceboNCT02192554 · 2014-06-01

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I DisorderNCT01981811 · 2014-03-01

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's TypeNCT01922258 · 2013-09-01

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's AgitationNCT01862640 · 2013-07-11

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With SchizophreniaNCT01909466 · 2013-07-01

The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-ADNCT01696591 · 2012-03-01

Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's DiseaseNCT01662414 · 2011-04-01

Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple SclerosisNCT01056471 · 2010-01-01

Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune MechanismsNCT00690196 · 2008-03-01

A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive ImpairmentNCT00240695 · 2003-05-01

A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's DiseaseNCT00291421 · 2002-07-01

Common interventions

Leading sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc. 6 Inmune Bio, Inc. 3 Radboud University Medical Center 3 Eli Lilly and Company 2 Herantis Pharma Plc. 2 University of Texas at Austin 2 Advanced Technology & Communications 1 Ageless Regenerative Institute 1 Amsterdam UMC, location VUmc 1 Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud 1 Beijing Friendship Hospital 1 Centre Hospitalier de PAU 1 Chulalongkorn University 1 Dragonfly Research, LLC 1 Duk Lyul Na 1

Trial status mix

COMPLETED27

RECRUITING10

UNKNOWN6

ACTIVE_NOT_RECRUITING3

TERMINATED3

WITHDRAWN3

SUSPENDED2

Phase mix

NA18

PHASE213

PHASE18

PHASE36

PHASE43

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.